Document is current
Any future updates will be listed below
-
Authors
Weidinger, Stephan https://orcid.org/0000-0003-3944-252X
Schadeck, Tobias
Jacobs, Felix
Weyergraf, Ansgar
Mortazawi, Dariusch
Hagemann, Tobias
Abousamra, Fatima
Mosch, Thomas
Fritz, Bjoern
Lauffer, Felix
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05139836 at ClinicalTrials.govDocuments that mention this clinical trial
Early Achievement of High Treatment Targets in Moderate-to-Severe Atopic Dermatitis with Upadacitinib: Real-World Evidence from the Observational UP-TAINED Study
https://doi.org/10.1007/s13555-025-01373-7
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
Received: 10 December 2024
Accepted: 24 February 2025
First Online: 15 March 2025
Declarations
:
: Stephan Weidinger received institutional research grants from LEO Pharma, Pfizer, and Sanofi Deutschland GmbH and lecture and/or consultancy fees from AbbVie, Almirall, Boehringer, Eli Lilly, Galderma, GSK, LEO Pharma, Pfizer, Regeneron, and Sanofi. He is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of psoriasis and atopic dermatitis. Tobias Schadeck participated in noninterventional trials for AbbVie. Felix Jacobs is a member of advisory boards and/or a speaker for AbbVie, Alliance Pharma, Almirall, Hermal, Janssen, Lilly, and Novartis. Ansgar Weyergraf served as a speaker, advisor, and/or researcher for AbbVie, Almirall, Amgen, Arctic Bioscience, Biogen, Bristol-Myers-Squibb, Celgene, Hermal, Janssen, LEO, Lilly, Novartis, Pfizer, Sanofi, and UCB. Dariusch Mortazawi was an advisor, received honoraria and grants, and/or participated in clinical trials for AbbVie, Almirall, Amgen, Celgene, Eli Lilly, Janssen-Cilag, LEO Pharma, Moberg Pharma, Novartis, Pfizer, Sandoz, Sanofi Genzyme, UCB Pharma, and Viatris. Tobias Hagemann is a member of advisory boards and/or a speaker for AbbVie, Almirall Hermal, Bencard Allergie GmbH, Pierre Fabre Dermatologie, Regeneron, and Sanofi-Aventis. Fatima Abousamra, Thomas Mosch, and Bjoern Fritz are employees of AbbVie and may own AbbVie stock. Felix Lauffer is a member of advisory boards and/or a speaker for AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol-Myers-Squibb, Janssen, LEO Pharma, Lilly, Novartis, Roche, Sanofi, UCB, and Union Therapeutics.
: According to the requirements for non-interventional, observational studies, no additional diagnostic or monitoring procedures or measurements that would not be feasible for use in routine clinical care were done in this study. Study-related monitoring, if applicable, was permitted by the study sites/investigators, including audits, independent ethics committee or independent review board review, and regulatory inspection(s). Ethics committee approval was obtained by the medical faculty in Kiel, Germany, on November 1, 2021.
